Abstract
10,11
The absence of successful therapies in this setting may, in part, stem from our limited understanding of the underlying pathophysiology and molecular profile of the different MDS/MPNs. Based on their known activity in myelofibrosis (MF) and MDS, a number of agents have been used for the treatment of patients with MDS/MPNs, with limited successes and a median overall survival (OS) of <2 years in most cases. [12] [13] [14] These included hydroxyurea, 15 alpha-interferon, 16, 17 hematopoietic growth factors, hypomethylating agents (HMAs), immunomodulatory drugs, and combination approaches (thalidomide, arsenic, dexamethasone, ascorbic acid). In MF the JAK1/2 inhibitor ruxolitinib resulted in the reduction of spleen size, control of symptoms, improvement in the quality of life and overall survival (OS). [18] [19] [20] HMAs improved cytopenias and OS and delayed the transformation to acute myeloid leukemia (AML) in patients with MDS 21, 22 and CMML. [23] [24] [25] [26] [27] HMAs have also shown activity in small studies and case-series in patients with MDS/MPN-U, 13 aCML, 28, 29 MF, 30, 31 and post-MPN AML. 32 The recent acceptance of MDS/MPNs as an independent entity, their heterogeneous presentation, and the lack of clearly defined molecular profiles, have resulted in a dearth of prospective clinical trial literature in this patient population. The independent activity of ruxolitinib and azacytidine in patients with MPNs and MDS, respectively, and their nonoverlapping toxicity profiles suggest that the combination of these two agents administered sequentially and at lower doses may be tolerable and efficacious in patients with MDS/MPNs. This is the first report of a prospective phase II trial evaluating the efficacy and safety of azacytidine with ruxolitinib in patients with MDS/MPNs.
| M E TH ODS

| Study design and participants
We conducted an open-label, nonrandomized phase II study of the 
| Treatment regimen
A sequential approach was adopted with single-agent ruxolitinib 5 mg orally twice daily administered continuously in 28-day cycles for the first 3 cycles if the baseline platelet count was 50-100 3 10 Treatment cycles were repeated every 4 to 6 weeks. Therapy was continued until disease progression, the development of unacceptable toxicity, concurrent illness preventing further treatment, or patient's request to withdraw from the study. Dose adjustments for adverse events (AEs) for grade 3 hematologic and nonhematologic drug-related toxicities were outlined in the protocol. Patients who received at least one dose of either study drug were eligible for efficacy and toxicity evaluation per an intent-to-treat approach.
| Outcomes
The primary objective was to determine the objective response rate The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Twelve of the 35 patients (34%) had received prior therapy for MDS/ MPN with the most prior therapies being hydroxyurea (n 5 12; 34%), and/or anagrelide (n 5 1; 3%), and/or pegylated interferon alfa-2a
(n 5 1; 3%). Targeted sequencing using the 28-gene panel 35 was performed in 34 of the 35 (97%) patients. Ten (29%) patients had JAK2V617 mutation. Other common mutations included RAS (27%), ASXL1 (21%), TET2 (18%), and DNMT3A (12%). Fifteen (44%) patients had more than one mutation.
| Response to therapy
The median number of administered cycles of ruxolitinib with or without azacytidine was 10 (range, 1-47); treatment is ongoing in 8 (23%)
patients. Azacytidine was administered in 32 of 35 (91%) patients.
Three (9%) patients never started the azacytidine due to prohibitive cytopenias. Eighteen of the 32 (56%) patients initiated the azacytidine earlier than cycle 4 due to rapidly proliferative disease or increased blasts (>10%) Table 2 . Ten patients had >5% pretreatment bone marrow blasts and 7 (70%) of these achieved a reduction in bone marrow blasts to <5%. A >50% reduction in palpable spleen length at 24 weeks was seen in 9 of 12 (75%) patients with pretreatment palpable spleen >5 cm below left subcostal margin ( Figure 1A) . Table S4 .
| Survival endpoints
The median duration of treatment in the study population was 13. 
| Safety
The median number of cycles of ruxolitinib received was 10 (range, 1-47) and the median number of cycles of azacytidine received was 8
(range, 0-42). The regimen was well tolerated with only one patient (3%) requiring therapy discontinuation due to thrombocytopenia.
The most commonly reported nonhematologic AEs of any grade irrespective of attribution were nausea and vomiting (23%), constipation (23%), diarrhea (9%), and abdominal pain (9%) ( Table 3) . These were transient with no patients requiring therapy discontinuation. New onset grade 3-4 hematologic AEs irrespective of attribution at any time on study included thrombocytopenia (54%), anemia (51%) and neutropenia (29%). These were manageable with dose modifications and/or short interruptions, with one patient requiring discontinuation of study therapy due to refractory cytopenias. Clinically, ruxolitinib has recently shown efficacy in patients with CMML-1 with particular benefit in proliferative patients. 41 Ruxolitinib may specifically offer benefit in the aCML patients with JAK2 or CSF3R 42,43 mutations and potentially in aCML patients not harboring these mutations (NCT02092324). HMA therapy produced a complete hematologic remission (CHR) in 7 of the 8 patients with aCML, described in 4 separate reports. 29 We aimed to derive synergistic benefit from the combination, with hypomethylation improving cytopenias and delaying progression to acute leukemia, 21, 44 while JAK/STAT-inhibition mitigating cytokine-related symptoms, splenomegaly, and reversing or stabilizing marrow fibrosis. 18, [45] [46] [47] Objective responses as defined by the 2015 ICP MDS/MPN 2015 criteria 36 were seen in 57% of the patients on this trial. As expected, the combination was particularly effective in improving proliferative features including ICP MDS/MPN reductions in palpable splenomegaly and improvements in the total symptom score by MPN-SAF, in 64%
and 78% of patients, respectively. Another encouraging response was the attainment of bone marrow morphologic remissions in 7 of 10 patients who had >5% bone marrow blasts at baseline. Bone marrow blast reduction is not frequently seen with single agent ruxolitinib in patients with MF 18, 48 and bone marrow blasts >10% is known to be an adverse prognostic factor for response to single-agent azacytidine in CMML, 49 indicating that achievement of bone marrow blast remissions in patients with MDS/MPNs may be one of the areas where the combination of azacytidine and ruxolitinib provided a specific advantage to either single agent alone.
Patients with a JAK2 mutation had a significantly higher ICP MDS/ MPN response rate as compared to patients without a JAK2 mutation on univariate analysis although responses were seen among both JAK2 mutated (n 5 10; response rate 5 90%) and nonmutated patients (n 5 24; response rate 5 29%). This is similar to what has been well (29) established with single agent ruxolitinib therapy in primary MF. 18, 19 Similarly, patients with baseline splenomegaly had higher response rates and this may be due to the fact that as opposed to patients without a baseline enlarged spleen these patients had the added possibility of being counted for spleen responses, an independent response cate- 
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